<DOC>
	<DOCNO>NCT02072954</DOCNO>
	<brief_summary>To compare evaluate oral bioavailability Asenapine Sublingual Tablets , 10 mg manufacture AMNEAL PHARMACEUTICALS , USA SAPHRIS® ( asenapine ) sublingual tablet , 10 mg .</brief_summary>
	<brief_title>Bioequivalence Fasting Study Patients</brief_title>
	<detailed_description>To compare evaluate oral bioavailability Asenapine Sublingual Tablets , 10 mg manufacture AMNEAL PHARMACEUTICALS , USA SAPHRIS® ( asenapine ) sublingual tablet , 10 mg follow multiple-dose administration adult human patient receive stable twice daily dose asenapine maleate EQ 10 mg base . To monitor safety tolerability multiple dos asenapine sublingual tablet 10 mg adult human patient receive stable twice daily dose asenapine maleate EQ 10 mg base .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Adult patient either sex age 18 65 year ( inclusive ) take stable dose asenapine maleate sublingual tablet , EQ 10 mg base twice daily therapy least three month . Willing able comply study visit schedule protocol requirement indicate signed write informed consent witness legally acceptable representative . Females childbearing ( complete 01 year menopause &amp; go hysterectomy bilateral tubal ligation ) potential must negative pregnancy test ( screen , randomization checkin housing ) well must nonlactating screening must agree use effective contraceptive method study . History allergic adverse reaction asenapine maleate olanzapine judge investigator If consume tobacco orally ( spit tobacco , gutka , pan masala , pan , etc . ) A history severe hepatic impairment , drug induce leukopenia/ neutropenia , congenital prolongation QT interval , cardiac arrhythmia , myocardial infarction unstable heart disease Concurrent primary psychiatric neurological diagnosis , include organic mental disorder , severe tardive dyskinesia , idiopathic Parkinson 's disease Abnormal laboratory result A history granulocytopenia myeloproliferative disorder ( druginduced idiopathic ) A medical surgical condition might interfere absorption , metabolism , excretion asenapine maleate History multiple syncopal episode History epilepsy risk seizures Any condition/ Abnormal baseline finding investigator ' judgment might increase risk patient ( e.g . Significant orthostatic hypotension define drop systolic blood pressure 30 mm Hg and/or drop diastolic blood pressure 20 mm Hg standing ) decrease chance obtain satisfactory data need obtain objective study . A history alcohol drug dependence DSMIV criterion 6month period immediately prior study entry Positive test drug alcohol abuse screen baseline Use follow medication 14 day precede enrollment : Strong CYP3A4 inhibitor , Strong CYP3A4 inducer , CYP1A2 inhibitor , Antihypertensive medication medication might predispose orthostatic hypotension , Drugs know suppress bone marrow function , medication know prolong QTc interval . Participation clinical study receipt treatment investigational drug device within 1 month prior Screening . Blood donation/ loss exceed 550 mL within last 90 day . Any expect change concomitant medication period study Compliance outpatient medication schedule expect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>